Palisade Bio, Inc. announced on May 6, 2025, the presentation of positive preclinical data for PALI-2108 at Digestive Disease Week (DDW) 2025. Two posters were presented, with one receiving the distinction of 'Poster of Distinction'.
The presented data highlighted PALI-2108's efficacy and safety profile in a mouse model of colitis, focusing on its impact on PDE4B expression, cAMP levels, and TNF-α suppression. Preclinical results indicated that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response.
Pharmacokinetic modeling using data from healthy volunteers suggested favorable absorption and bioavailability, supporting PALI-2108's potential for clinical use. The company continues to make progress in its ongoing Phase 1a/b study of PALI-2108 in UC and expects to report topline data from the completed Phase 1a portion by the end of May 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.